Sabra Reports Third Quarter 2019 Results; Continues to Improve Leverage and Other Credit Metrics; Reaffirms 2019 Guidance

IRVINE, Calif.–(BUSINESS WIRE)–#Healthcare–Sabra Health Care REIT, Inc. (“Sabra,” the “Company” or “we”) (Nasdaq:SBRA) today announced results of operations for the third quarter of 2019.

RECENT HIGHLIGHTS

For the third quarter of 2019, net income attributable to common stockholders, FFO, Normalized FFO, AFFO and Normalized AFFO per diluted common share were $0.12, $0.45, $0.47, $0.46 and $0.47, respectively.

In our managed portfolio:

 

Our wholly-owned Senior Housing – Managed portfolio produced net income of $5.7 million and $2.1 million for the third quarter of 2019 and 2018, respectively, and same store year-over-year Cash NOI growth of 9.7%.

 

Our unconsolidated joint venture produced a net loss of $0.6 million and $1.7 million for the third quarter of 2019 and 2018, respectively, and same store year-over-year Cash NOI growth of 15.3%.

During the third quarter of 2019, we made investments of $20.6 million with a weighted average initial cash yield of 8.65%, including a $14.8 million investment in two addiction treatment facilities under a 15 year triple-net lease having an initial cash lease yield of 9% with annual escalators equal to the greater of 2% and CPI.

We continued to improve our leverage, cost of capital and other credit metrics during this quarter:

 

On September 9, 2019, we closed on our previously announced $2.2 billion (U.S. $2.1 billion plus CAD $125.0 million) credit facility amendment, which lowered interest rate spreads for revolver borrowings and term loan borrowings by 15 basis points and 20 basis points, respectively, based on our current credit rating. The amendment also improved our debt maturities laddering by extending the maturity for the revolver to September 2023 (compared to August 2021) and created additional laddering of our term loans with various maturities through September 2024 (compared to maturity dates through August 2022). Based on outstanding borrowings as of September 30, 2019, the annual interest savings from this amendment is $2.7 million.

 

During the third quarter of 2019, we sold 4.2 million shares of common stock under our ATM Program, generating gross proceeds of $91.2 million, before $1.3 million of commissions. These proceeds were primarily used to repay $75.0 million of amounts outstanding under our revolving credit facility, which resulted in a reduction of our Net Debt to Adjusted EBITDA ratio (including our unconsolidated joint venture) from 5.76x as of June 30, 2019 to 5.70x as of September 30, 2019.

 

In addition, these transactions improved the following key credit metrics compared to the second quarter of 2019:

 

 

Interest Coverage improved 0.35x, increasing to 4.97x

 

 

Fixed Charge Coverage improved 0.26x, increasing to 4.72x

 

 

Total Debt/Asset Value improved 1%, decreasing to 38%

 

 

For additional detail and information regarding these key credit metrics, refer to the Credit Metrics and Ratings section of our corresponding Supplemental Report, available in the Investor Relations section of our website at http://www.sabrahealth.com/investors/financials/reports-presentations.

 

Finally, on October 7, 2019, we issued $350.0 million of 3.90% senior unsecured notes due 2029. The net proceeds were used to redeem all $200.0 million of our outstanding 5.375% senior unsecured notes due 2023 and repay amounts outstanding under our revolving credit facility. This refinancing of our senior unsecured notes is expected to result in $1.9 million of annual interest savings and will further reduce our cost of permanent debt to 3.81% from 3.91% as of September 30, 2019.

We reaffirm our previously issued earnings guidance with the following updates to our expectations for the fourth quarter of 2019:

 

Total interest expense for the fourth quarter of 2019 is expected to be $27.5 million.

 

Capital expenditures (Senior Housing – Managed and non-yielding triple-net) for the fourth quarter of 2019 are expected to total $4.9 million.

 

Investments for the fourth quarter of 2019, primarily related to our propriety development pipeline, are expected to total $56 million with an average initial cash yield of 6.5%, with the majority expected to be completed at the end of the fourth quarter.

 

Dispositions and paydowns of the Company’s loans receivable and preferred equity investments in the fourth quarter of 2019 are expected to total $16 million with associated annualized Cash NOI of $0.7 million.

 

These updates continue to be based on our expectation of reducing our Net Debt to Adjusted EBITDA ratio (including our unconsolidated joint venture) to below 5.50x (below 5.0x excluding our unconsolidated joint venture) by December 31, 2019.

On October 30, 2019, we announced that our board of directors declared a quarterly cash dividend of $0.45 per share of common stock. The dividend will be paid on November 29, 2019 to common stockholders of record as of the close of business on November 15, 2019.

Commenting on the third quarter results, Rick Matros, CEO and Chairman, said, “We continued to execute our strategy and make meaningful improvements to our balance sheet this quarter. We look forward to hitting our target leverage of 5.50x Net Debt to Adjusted EBITDA or better by year end. That will position us to enter 2020 with all balance sheet initiatives completed and positions us with the strongest balance sheet since the Company’s inception.

“Operationally, our portfolio was stable. Senior Housing – Managed growth was quite strong. Skilled Nursing/Transitional Care and Senior Housing EBITDAR coverages were flat, while hospital coverage was up. Same store Skilled Nursing/Transitional Care and Senior Housing occupancy ticked up. Although hospital occupancy was down, this population remains more dynamic with shorter and less predictable lengths of stays.

“The one Skilled Nursing/Transitional Care tenant that was down most noticeably was Avamere. This was a function of Avamere’s ancillary companies, which had gone through a major software conversion. The facility performance was stable, and we expect the ancillary businesses to recover over the next couple of quarters.

“Our Skilled Nursing/Transitional Care tenants reported a smooth transition to PDPM. While it is still too early to accurately gauge the benefits, our tenants’ perspective remains universally positive.”

LIQUIDITY

As of September 30, 2019, we had approximately $829.4 million of liquidity, consisting of unrestricted cash and cash equivalents of $29.4 million and available borrowings of $800.0 million under our revolving credit facility. As of September 30, 2019, we also had $191.5 million available under the ATM Program.

CONFERENCE CALL AND COMPANY INFORMATION

A conference call with a simultaneous webcast to discuss the 2019 third quarter results will be held on Thursday, October 31, 2019 at 10:00 am Pacific Time. The dial-in number for U.S. participants is (844) 862-3710. For participants outside the U.S., the dial-in number is (612) 979-9902. The conference ID number is 3958455. The webcast URL is https://edge.media-server.com/mmc/p/pi8rthqz. A digital replay of the call will be available on the Company’s website at www.sabrahealth.com. The Company’s supplemental information package for the third quarter will also be available on the Company’s website in the “Investors” section.

ABOUT SABRA

As of September 30, 2019, Sabra’s investment portfolio included 434 real estate properties held for investment (consisting of (i) 304 Skilled Nursing/Transitional Care facilities, (ii) 62 Senior Housing communities (“Senior Housing – Leased”), (iii) 44 Senior Housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing – Managed”) and (iv) 24 Specialty Hospitals and Other facilities), one investment in a direct financing lease, 20 investments in loans receivable (consisting of (i) one mortgage loan, (ii) two construction loans and (iii) 17 other loans), nine preferred equity investments and one investment in an unconsolidated joint venture that owns 170 Senior Housing – Managed communities. As of September 30, 2019, Sabra’s real estate properties held for investment included 43,553 beds/units and its unconsolidated joint venture included 7,538 beds/units, spread across the United States and Canada.

FORWARD-LOOKING STATEMENTS SAFE HARBOR

This release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified, without limitation, by the use of “expects,” “believes,” “intends,” “should” or comparable terms or the negative thereof. Examples of forward-looking statements include all statements regarding our de-levering activity, and our tenants’ financial performance, as well as our expected future financial position, results of operations (including our expectations for the fourth quarter of 2019), business strategy, and plans and objectives for future operations, capital raising activity and operator restructurings.

Our actual results may differ materially from those projected or contemplated by our forward-looking statements as a result of various factors, including among others, the following: our dependence on the operating success of our tenants; the potential variability of our reported rental and related revenues following the adoption of Accounting Standards Update (“ASU”) 2016-02, Leases, as amended by subsequent ASUs (“Topic 842”) on January 1, 2019; operational risks with respect to our Senior Housing – Managed communities; the effect of our tenants declaring bankruptcy or becoming insolvent; our ability to find replacement tenants and the impact of unforeseen costs in acquiring new properties; the impact of litigation and rising insurance costs on the business of our tenants; the possibility that Sabra may not acquire the remaining majority interest in the Enlivant joint venture; risks associated with our investments in joint ventures; changes in healthcare regulation and political or economic conditions; the impact of required regulatory approvals of transfers of healthcare properties; competitive conditions in our industry; our concentration in the healthcare property sector, particularly in skilled nursing/transitional care facilities and senior housing communities, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries; the significant amount of and our ability to service our indebtedness; covenants in our debt agreements that may restrict our ability to pay dividends, make investments, incur additional indebtedness and refinance indebtedness on favorable terms; increases in market interest rates; the potential phasing out of the London Interbank Offered Rate (“LIBOR”) benchmark after 2021; our ability to raise capital through equity and debt financings; changes in foreign currency exchange rates; the relatively illiquid nature of real estate investments; the loss of key management personnel; uninsured or underinsured losses affecting our properties and the possibility of environmental compliance costs and liabilities; the impact of a failure or security breach of information technology in our operations; our ability to maintain our status as a real estate investment trust (“REIT”); changes in tax laws and regulations affecting REITs (including the potential effects of the Tax Cuts and Jobs Act); compliance with REIT requirements and certain tax and tax regulatory matters related to our status as a REIT; and the ownership limits and takeover defenses in our governing documents and under Maryland law, which may restrict change of control or business combination opportunities.

Additional information concerning risks and uncertainties that could affect our business can be found in our filings with the Securities and Exchange Commission (the “SEC”), including in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018 and in Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019. We do not intend, and we undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, unless required by law to do so.

TENANT AND BORROWER INFORMATION

This release includes information regarding certain of our tenants that lease properties from us and our borrowers, most of which are not subject to SEC reporting requirements. The information related to our tenants and borrowers that is provided in this release has been provided by, or derived from information provided by, such tenants and borrowers. We have not independently verified this information. We have no reason to believe that such information is inaccurate in any material respect. We are providing this data for informational purposes only.

NOTE REGARDING NON-GAAP FINANCIAL MEASURES

This release includes the following financial measures defined as non-GAAP financial measures by the SEC: net operating income (“NOI”), Cash NOI, funds from operations attributable to common stockholders (“FFO”), Normalized FFO, Adjusted FFO (“AFFO”), Normalized AFFO, FFO per diluted common share, Normalized FFO per diluted common share, AFFO per diluted common share and Normalized AFFO per diluted common share. These measures may be different than non-GAAP financial measures used by other companies, and the presentation of these measures is not intended to be considered in isolation or as a substitute for financial information prepared and presented in accordance with U.S. generally accepted accounting principles. An explanation of these non-GAAP financial measures is included under “Reporting Definitions” in this release, and reconciliations of these non-GAAP financial measures to the GAAP financial measures we consider most comparable are included on the Investors section of our website at http://www.sabrahealth.com/investors/financials/reports-presentations/non-gaap.

 

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(dollars in thousands, except per share data)

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2019

 

2018

 

2019

 

2018

Revenues:

 

 

 

 

 

 

 

Rental and related revenues

$

110,104

 

 

$

130,467

 

 

$

339,291

 

 

$

418,951

 

Interest and other income

3,325

 

 

3,932

 

 

77,145

 

 

12,823

 

Resident fees and services

36,405

 

 

17,403

 

 

89,537

 

 

52,426

 

 

 

 

 

 

 

 

 

Total revenues

149,834

 

 

151,802

 

 

505,973

 

 

484,200

 

 

 

 

 

 

 

 

 

Expenses:

 

 

 

 

 

 

 

Depreciation and amortization

43,092

 

 

48,468

 

 

137,517

 

 

143,301

 

Interest

29,255

 

 

37,305

 

 

99,181

 

 

109,880

 

Triple-net portfolio operating expenses

5,611

 

 

 

 

17,140

 

 

 

Senior housing – managed portfolio operating expenses

23,979

 

 

12,611

 

 

60,258

 

 

37,034

 

General and administrative

8,709

 

 

8,173

 

 

24,952

 

 

25,753

 

Provision for doubtful accounts, straight-line rental income and loan losses

57

 

 

8,910

 

 

1,457

 

 

9,449

 

Impairment of real estate

13,966

 

 

 

 

119,102

 

 

1,413

 

 

 

 

 

 

 

 

 

Total expenses

124,669

 

 

115,467

 

 

459,607

 

 

326,830

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

Loss on extinguishment of debt

(644

)

 

 

 

(10,763

)

 

 

Other income

215

 

 

1,336

 

 

385

 

 

4,156

 

Net (loss) gain on sales of real estate

(19

)

 

14

 

 

1,216

 

 

142,445

 

 

 

 

 

 

 

 

 

Total other income (expense)

(448

)

 

1,350

 

 

(9,162

)

 

146,601

 

 

 

 

 

 

 

 

 

Income before loss from unconsolidated joint venture and income tax expense

24,717

 

 

37,685

 

 

37,204

 

 

303,971

 

 

 

 

 

 

 

 

 

Loss from unconsolidated joint venture

(605

)

 

(1,725

)

 

(5,635

)

 

(3,626

)

Income tax expense

(826

)

 

(732

)

 

(2,292

)

 

(1,847

)

 

 

 

 

 

 

 

 

Net income

23,286

 

 

35,228

 

 

29,277

 

 

298,498

 

 

 

 

 

 

 

 

 

Net income attributable to noncontrolling interests

(4

)

 

(10

)

 

(22

)

 

(22

)

 

 

 

 

 

 

 

 

Net income attributable to Sabra Health Care REIT, Inc.

23,282

 

 

35,218

 

 

29,255

 

 

298,476

 

 

 

 

 

 

 

 

 

Preferred stock dividends

 

 

 

 

 

 

(9,768

)

 

 

 

 

 

 

 

 

Net income attributable to common stockholders

$

23,282

 

 

$

35,218

 

 

$

29,255

 

 

$

288,708

 

 

 

 

 

 

 

 

 

Net income attributable to common stockholders, per:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic common share

$

0.12

 

 

$

0.20

 

 

$

0.16

 

 

$

1.62

 

 

 

 

 

 

 

 

 

Diluted common share

$

0.12

 

 

$

0.20

 

 

$

0.16

 

 

$

1.62

 

 

 

 

 

 

 

 

 

Weighted-average number of common shares outstanding, basic

190,650,400

 

 

178,317,769

 

 

183,578,254

 

 

178,309,127

 

 

 

 

 

 

 

 

 

Weighted-average number of common shares outstanding, diluted

191,952,389

178,941,213

184,698,411

178,729,853

 

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(dollars in thousands, except per share data)

 

 

September 30, 2019

 

December 31, 2018

 

(unaudited)

 

 

Assets

 

 

 

Real estate investments, net of accumulated depreciation of $502,777 and $402,338 as of September 30, 2019 and December 31, 2018, respectively

$

5,344,997

 

 

$

5,853,545

 

Loans receivable and other investments, net

108,242

 

 

113,722

 

Investment in unconsolidated joint venture

324,324

 

 

340,120

 

Cash and cash equivalents

29,431

 

 

50,230

 

Restricted cash

10,231

 

 

9,428

 

Lease intangible assets, net

104,977

 

 

131,097

 

Accounts receivable, prepaid expenses and other assets, net

145,801

 

 

167,161

 

Total assets

$

6,068,003

 

 

$

6,665,303

 

 

 

 

 

Liabilities

 

 

 

Secured debt, net

$

113,644

 

 

$

115,679

 

Revolving credit facility

200,000

 

 

624,000

 

Term loans, net

1,182,983

 

 

1,184,930

 

Senior unsecured notes, net

1,106,484

 

 

1,307,394

 

Accounts payable and accrued liabilities

109,401

 

 

94,827

 

Lease intangible liabilities, net

73,074

 

 

83,726

 

Total liabilities

2,785,586

 

 

3,410,556

 

 

 

 

 

Equity

 

 

 

Common stock, $.01 par value; 250,000,000 shares authorized, 193,696,901 and 178,306,528 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively

1,937

 

 

1,783

 

Additional paid-in capital

3,823,584

 

 

3,507,925

 

Cumulative distributions in excess of net income

(523,709

)

 

(271,595

)

Accumulated other comprehensive (loss) income

(19,395

)

 

12,301

 

Total Sabra Health Care REIT, Inc. stockholders’ equity

3,282,417

 

 

3,250,414

 

Noncontrolling interests

 

 

4,333

 

Total equity

3,282,417

 

 

3,254,747

 

Total liabilities and equity

$

6,068,003

 

 

$

6,665,303

 

 

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

 

Nine Months Ended September 30,

 

2019

 

2018

Cash flows from operating activities:

 

 

 

Net income

$

29,277

 

 

$

298,498

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Depreciation and amortization

137,517

 

 

143,301

 

Amortization of above and below market lease intangibles, net

1,102

 

 

4,193

 

Non-cash interest income adjustments

(1,680

)

 

(1,722

)

Non-cash interest expense

7,846

 

 

7,548

 

Stock-based compensation expense

8,829

 

 

6,275

 

Non-cash lease termination income

(9,725

)

 

 

Loss on extinguishment of debt

10,763

 

 

 

Straight-line rental income adjustments

(14,067

)

 

(34,404

)

Provision for doubtful accounts, straight-line rental income and loan losses

1,457

 

 

9,449

 

Net gain on sales of real estate

(1,216

)

 

(142,445

)

Impairment of real estate

119,102

 

 

1,413

 

Loss from unconsolidated joint venture

5,635

 

 

3,626

 

Distributions of earnings from unconsolidated joint venture

10,162

 

 

6,494

 

Changes in operating assets and liabilities:

 

 

 

Accounts receivable, prepaid expenses and other assets, net

(7,252

)

 

(4,031

)

Accounts payable and accrued liabilities

(20,769

)

 

(15,171

)

Net cash provided by operating activities

276,981

 

 

283,024

 

Cash flows from investing activities:

 

 

 

Acquisition of real estate

(14,977

)

 

(239,001

)

Origination and fundings of loans receivable

(9,441

)

 

(41,448

)

Origination and fundings of preferred equity investments

 

 

(5,285

)

Additions to real estate

(15,985

)

 

(21,695

)

Repayments of loans receivable

13,761

 

 

48,282

 

Repayments of preferred equity investments

3,672

 

 

6,491

 

Investment in unconsolidated joint venture

 

 

(354,461

)

Net proceeds from the sales of real estate

321,715

 

 

290,864

 

Buyout of noncontrolling interests

(200

)

 

 

Net cash provided by (used in) investing activities

298,545

 

 

(316,253

)

Cash flows from financing activities:

 

 

 

Net repayments of revolving credit facility

(424,000

)

 

(22,000

)

Proceeds from issuance of senior unsecured notes

297,039

 

 

 

Principal payments on senior unsecured notes

(500,000

)

 

 

Principal payments on secured debt

(2,566

)

 

(3,202

)

Payments of deferred financing costs

(14,001

)

 

(12

)

Payments related to extinguishment of debt

(6,897

)

 

 

Distributions to noncontrolling interests

(116

)

 

(107

)

Preferred stock redemption

 

 

(143,750

)

Issuance of common stock, net

302,030

 

 

(499

)

Dividends paid on common and preferred stock

(247,222

)

 

(244,978

)

Net cash used in financing activities

(595,733

)

 

(414,548

)

Net decrease in cash, cash equivalents and restricted cash

(20,207

)

 

(447,777

)

Effect of foreign currency translation on cash, cash equivalents and restricted cash

211

 

 

(156

)

Cash, cash equivalents and restricted cash, beginning of period

59,658

 

 

587,449

 

Cash, cash equivalents and restricted cash, end of period

$

39,662

 

 

$

139,516

 

Supplemental disclosure of cash flow information:

 

 

 

Interest paid

$

100,230

 

 

$

111,519

 

 

SABRA HEALTH CARE REIT, INC.

FUNDS FROM OPERATIONS (FFO), NORMALIZED FFO,

ADJUSTED FUNDS FROM OPERATIONS (AFFO) AND NORMALIZED AFFO

(dollars in thousands, except per share data)

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2019

 

2018

 

2019

 

2018

Net income attributable to common stockholders

$

23,282

 

 

$

35,218

 

 

$

29,255

 

 

$

288,708

 

Add:

 

 

 

 

 

 

 

Depreciation and amortization of real estate assets

43,092

 

 

48,468

 

 

137,517

 

 

143,301

 

Depreciation and amortization of real estate assets related to noncontrolling interests

(14

)

 

(39

)

 

(93

)

 

(119

)

Depreciation and amortization of real estate assets related to unconsolidated joint venture

5,439

 

 

5,214

 

 

16,102

 

 

15,929

 

Net loss (gain) on sales of real estate

19

 

 

(14

)

 

(1,216

)

 

(142,445

)

Net loss on sales of real estate related to unconsolidated joint venture

 

 

 

 

1,690

 

 

 

Impairment of real estate

13,966

 

 

 

 

119,102

 

 

1,413

 

FFO attributable to common stockholders

$

85,784

 

 

$

88,847

 

 

$

302,357

 

 

$

306,787

 

Lease termination income

 

 

 

 

(66,948

)

 

 

Loss on extinguishment of debt

644

 

 

 

 

10,763

 

 

 

Provision for doubtful accounts and loan losses, net

57

 

 

10,860

 

 

1,457

 

 

5,568

 

Other normalizing items (1)

3,623

 

 

6,810

 

 

12,542

 

 

11,122

 

Normalized FFO attributable to common stockholders

$

90,108

 

 

$

106,517

 

 

$

260,171

 

 

$

323,477

 

FFO attributable to common stockholders

$

85,784

 

 

$

88,847

 

 

$

302,357

 

 

$

306,787

 

Merger and acquisition costs

130

 

 

151

 

 

192

 

 

593

 

Stock-based compensation expense

3,259

 

 

2,436

 

 

8,829

 

 

6,275

 

Straight-line rental income adjustments

(3,357

)

 

(10,652

)

 

(14,067

)

 

(34,404

)

Amortization of above and below market lease intangibles, net

(1,601

)

 

5,561

 

 

1,102

 

 

4,193

 

Non-cash interest income adjustments

(555

)

 

(548

)

 

(1,680

)

 

(1,722

)

Non-cash interest expense

2,523

 

 

2,551

 

 

7,846

 

 

7,548

 

Non-cash portion of loss on extinguishment of debt

642

 

 

 

 

3,866

 

 

 

Provision for doubtful straight-line rental income, loan losses and other reserves

57

 

 

8,801

 

 

1,457

 

 

11,293

 

Non-cash lease termination income

 

 

 

 

(9,725

)

 

 

Other non-cash adjustments related to unconsolidated joint venture

777

 

 

118

 

 

2,923

 

 

1,132

 

Other non-cash adjustments

(3

)

 

25

 

 

95

 

 

55

 

AFFO attributable to common stockholders

$

87,656

 

 

$

97,290

 

 

$

303,195

 

 

$

301,750

 

Cash portion of lease termination income

 

 

 

 

(57,223

)

 

 

Cash portion of loss on extinguishment of debt

2

 

 

 

 

6,897

 

 

 

Provision for (recovery of) doubtful cash income

 

 

108

 

 

 

 

(2,160

)

Other normalizing items (1)

2,050

 

 

466

 

 

5,067

 

 

4,372

 

Normalized AFFO attributable to common stockholders

$

89,708

 

 

$

97,864

 

 

$

257,936

 

 

$

303,962

 

Amounts per diluted common share attributable to common stockholders:

 

 

 

 

 

 

 

Net income

$

0.12

 

 

$

0.20

 

 

$

0.16

 

 

$

1.62

 

FFO

$

0.45

 

 

$

0.50

 

 

$

1.64

 

 

$

1.72

 

Normalized FFO

$

0.47

 

 

$

0.60

 

 

$

1.41

 

 

$

1.81

 

AFFO

$

0.46

 

 

$

0.54

 

 

$

1.63

 

 

$

1.68

 

Normalized AFFO

$

0.47

 

 

$

0.55

 

 

$

1.39

 

 

$

1.69

 

Weighted average number of common shares outstanding, diluted:

 

 

 

 

 

 

 

Net income, FFO and Normalized FFO

191,952,389

 

 

178,941,213

 

 

184,698,411

 

 

178,729,853

 

AFFO and Normalized AFFO

192,590,320

 

 

179,469,883

 

 

185,480,674

 

 

179,428,243

 

Contacts

Investor & Media Inquiries:

(888) 393-8248

investorinquiries@sabrahealth.com

Read full story here

Author: dmnnewswire